Biologics Outsourcing Global Market-Forecast to 2030

Publishing Date : November, 2022
Report Code : HCPH0110
Price:
Single license $7,200
Site license $9,000
Global license $12,000


Note: The report would be dispatched after confirmation of payment

 

Biologics are the therapeutic entities composed of sugars, proteins, or nucleic acids and made from natural sources such as human, animal or microorganisms. Biologics also include live attenuated microorganisms (vaccines), allergenic extracts (allergy shots), human cells and tissues (for transplantation), cell and gene therapeutics. Similar to the conventional therapeutics, these drugs help in treating several diseases but are highly specific and more efficient in their disease healing mechanisms. The biologic entities like monoclonal antibodies and recombinant proteins target specific areas during their molecular mechanism of disease curing.

Even though biologics are highly expensive when compared to the conventional small molecule drugs, these target specific therapeutics have proven to be very beneficial for patients and also ensure higher profit margins to the drug manufacturers. The escalating adoption of biologics and elevating demand for the highly efficient biotherapeutics from the value-centric patient population across the globe, increasing investments on research and developmental activities of biologics and advanced, next-generation biotherapeutics, a favorable and streamlined regulatory environment that is expediting the novel product approval process and the expansion of biosimilar market have all led to the rapid growth of the biopharmaceutical market. Due to the increasing demand for biologics drugs and increased regulatory approvals for these drugs, there is huge demand for biologics manufacture and testing at various levels of clinical studies as well as commercial supply. This fast pacing biologic industry coupled with insufficient or lack of in house biologic development and manufacturing capabilities and capacities of biopharmaceutical companies has spurred these companies to outsource the different parts of biologic development and manufacturing process to highly efficient service providing organizations. The Large Biopharma companies are coming up with strategies to cut down on their operational costs and concentrate more on their core competencies by outsourcing this piece of work to contract research organizations (CROs), contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs). These organizations bridge the gap between demand and supply and ensure the drug discovery and manufacturing process gets much faster and convenient; thus bringing the life-saving drugs to the market and the needy patients at the earliest.

The biologics outsourcing global market is expected to grow at a double digit CAGR from 2022 to 2030 to reach $106.7 billion by 2030. Major drivers for the biologics outsourcing market include increasing trend of outsourcing among the biopharma companies for gaining an economical access to advanced biologics development and manufacturing capacities and capabilities, advanced bioprocessing capabilities of bioservice providers, increasing approvals and adoption of biologics, increasing R&D spend of biopharma companies and escalating approvals and uptake of biosimilars. Factors like emergence of next generation biotherapeutics, development of personalized and orphan indication therapies and the persistently escalating prevalence of chronic, communicable and autoimmune diseases are expected to boost the market growth. However, increasing focus on in-house biologics manufacturing, huge capital investments for capacity and capability development and compliance with stringent regulatory guidelines are restraining the market.

The biologics outsourcing global market has been segmented based on the developmental phase, product, end users and geography. Among the discovery, pre-clinical, clinical and commercial phases of biologics development, Commercial Phase outsourcing commanded the highest revenue in 2022 and is expected to grow at a double digit CAGR from 2022 to 2030. Clinical outsourcing segment is expected grow early teen CAGR from 2022 to 2030. The biological outsourcing market by product type is segmented into Antibody, Proteins, Vaccines, Gene therapy, cell therapy and others. Among these, the antibody outsourcing segment accounted for the highest revenue in 2022 and is expected to grow at a high single digit CAGR from 2022 to 20230. Gene therapeutics segment is expected grow at a high double digit CAGR from 2022 to 2030. Based on end-users, biologics outsourcing global market is segmented into Therapeutics, Diagnostics and Research. Among these, Therapeutics accounted for the highest revenue in 2022 and is expected to grow at a double digit CAGR from 2022 to 2030. Based on geography, biologics outsourcing global market is segmented into North America, Europe, Asia-Pacific and RoW. North America dominated the biologics outsourcing market with the highest revenue in 2022 and is expected to grow at high single digit CAGR 2022 to 2030. Whereas, Asia Pacific region is expected to be grow at an early teen CAGR from 2022 to 2030.

The report specifically emphasizes on the rapidly evolving and high growth potential biologics contract manufacturing services market and cell line development services market. The biologics contract manufacturing global market is expected to grow at double digit CAGR from 2022 to 2030. The contract biomanufacturing global market is driven by the increasing trend of outsourcing among the biopharmaceutical companies, availability of advanced bioprocessing capabilities among the contract bioservice providers, expansion of manufacturing facilities, and the escalating approval and adoption of biologics and the cost effective biosimilars among the value centric global patient pool leading to huge volume demand for biologics. Emergence of advanced biotherapeutics, increasing R&D investments by the biopharma companies, development of precision and orphan indication therapies and the persistently increasing prevalence of chronic, communicable and autoimmune diseases are also boosting contract biomanufacturing market growth.

The biologics contract biomanufacturing services global market is classified based on product, developmental phase, process, end users and geography. Based on the product, the biologics CMO global market divided into Drug substance manufacturing and Drug product manufacturing. Among these, drug substance manufacturing accounted for the highest revenue in 2022 and is expected to grow at a double digit CAGR from 2022 to 2030. The Drug Product manufacturing is expected to grow at an early teen CAGR from 2022 to 2030. Based on the developmental phase, the contract Biomanufacturing global market has been segmented as clinical phase contract biomanufacturing and commercial phase contract biomanufacturing. Among these phases, the commercial phase contract biomanufacturing accounted for the highest revenue in 2022 and is expected to grow at a double digit CAGR from 2022 to 2030. Clinical segment is expected to grow at an early teen CAGR from 2022 to 2030. Based on the process of contract biomanufacturing, the global market has been grouped into mammalian contract biomanufacturing, microbial contract biomanufacturing and other contract biomanufacturing processes (plant or insect cell based). Among these, mammalian cell culture CMO market is accounted for the highest revenue in 2022 and is expected to grow at an early teen CAGR from 2022 to 2030. The contract biomanufacturing services global market, based on end-users has been segmented into contract biomanufacturing for diagnostics, research reagents and therapeutics. Among these, contract biomanufacturing of therapeutics accounted for the highest revenue in 2022 and is expected to grow at an early teen CAGR from 2022 to 2030. Research segment is expected to grow at an early teen CAGR from 2022 to 2030. The vectors are basic important components in the development of biological modalities such as gene therapy, cell therapy, vaccines and also in the development of recombinant cell lines CHO and others for the production of biologics such as monoclonal antibodies, recombinant proteins and others. The Viral Vector & Plasmid DNA Contract Manufacturing global market is estimated to be $XX million in 2022 and is expected to grow at early teen CAGR from 2022 to 2030. Based on vector type, Viral Vector & Plasmid DNA Contract Manufacturing global market is divided into viral vector and plasmid DNA manufacturing. Among these, Plasmid DNA Contract Manufacturing segment is accounted for the highest revenue in 2022 and is expected to grow at a mid single digit CAGR from 2022 to 2030. Viral vector Contract Manufacturing is expected to grow at a high teen CAGR from 2022 to 2030. Based on modalities, Viral Vector and Plasmid DNA contract manufacturing global market is segmented into Vaccines, Cell & Gene Therapies and Others. Among these, Vaccines segment is accounted for the highest revenue in 2022 and is expected to grow at a high single digit CAGR from 2022 to 2030. Cell & Gene Therapies is expected to grow at a high double digit CAGR from 2022 to 2030. Based on the facility type, it can be categorized into Stainless steel and Single-use. Stainless steel CMO global manufacturing capacity is estimated to be XX million L in 2022 and is expected to grow at a high single digit CAGR from 2022 to 2030. Single-Use CMO global manufacturing capacity is expected to grow at a high double digit CAGR from 2022 to 2030. The contract biomanufacturing services global market based on geography is segmented into North America, Europe, Asia-Pacific and the Rest of the world (ROW). North America contributed highest revenue in 2022 and is growing at a high single digit CAGR from 2022 to 2030. Asia Pacific region is expected to grow at a early teen CAGR from 2022 to 2030.

The cell line development service market is expected to grow at a double digit CAGR from 2022 to 2030 to reach $2,093.2 million by 2030. Increasing demand for monoclonal antibodies, recombinant proteins and vaccines, growing incidence rate of oncology, autoimmune disorders, infectious diseases & genetic disorders and growth in research activities related to the diseases and also recombinant cell lines for the production recombinant biopharmaceutical proteins are driving the market. Technological advancements in cell line engineering (gene editing tools) & cell line development technologies, screening technologies and process development are giving immense growth opportunities for the market. However, complexities in the development of stable cell lines and high risk of contamination due to complex purification methods are restraining the market. Furthermore, stringent and complex regulations and the high cost and technical requirement to adhere to accreditations such as GMP are posing threat to the industry.

Cell line development service global market is classified based on the expression system, cell line type, application and geography. Based on expression system, cell line development service global market is segmented into microbial, mammalian and others. Among these, mammalian expression system is accounted for the highest revenue of in 2022 and is expected to grow at a double digit CAGR from 2022 to 2030. Based on the cell line type, global cell line development service market is segmented into CHO, Mouse Myeloma (NS0; Sp2/0), Human Embryonic Kidney (HEK), Baby Hamster Kidney (BHK), Hybridoma, Human Embryonic Retina (PER.C6) and others. Among these, CHO cell line accounted for the highest revenue in 2022 and is expected to grow at an early teen CAGR from 2022 to 2030. Based on application, cell line development service global market is segmented into research, bio production and diagnostics. Among these, bioproduction segment accounted for the highest revenue in 2022 and is expected to grow at a double digit CAGR from 2022 to 2030. Based on the geography, cell line development service global market is segmented into North America, Europe, Asia-Pacific and Rest of the world. North America commanded the highest revenue in 2022. The market is expected to grow at a high single digit CAGR from 2022 to 2030. Asia Pacific is expected to grow at an early teen CAGR from 2022 to 2030.

The top players in biologics outsourcing global market are Lonza (Switzerland), Catalent (U.S.), SamSung Biologics (South Korea), WuXi Biologics (China), Thermo Fisher (Patheon N.V.+Brammer Bio) (U.S.), FUJIFILM Holdings Corporation (FujiFilm Diosynth) (Japan), Merck KGaA (Germany), Boehringer Ingelheim (Germany), Laboratory Corporation of America Holdings (U.S.), Charles River Laboratories (U.S.), JSR corporation (U.S.), WuXi Apptech (China), Genscript Biotech Corporation (China), Emergent Biosciences (U.S.), Asahi Glass Company (AGC Biologics) (Japan) and others.

 

  • 1     BIOLOGICS OUTSOURCING GLOBAL MARKET
    • 1.1     EXCEUTIVE SUMMARY
    • 1.2     LANDSCAPE OF BIOLOGICS MARKET
    • 1.3     RISE OF BIOSIMILARS
    • 1.4     BIOSIMILARS GLOBAL MARKET, BY REGION
    • 1.5     BIOLOGICS GLOBAL MARKET
    • 1.6     TOP DESTINATION FOR BIOLOGICS OUTSOURCING
      • 1.6.1     CHINA BIOLOGICS OUTSOURCING MARKET
      • 1.6.2     INDIA BIOLOGICS OUTSOURCING MARKET
      • 1.6.3     CHINA VS INDIA - BIOLOGICS MARKET
      • 1.6.4     REGULATIONS AND GOVERNMENT INITIATIVES
      • 1.6.5     CAPABILITIES AND TECHNOLOGIES
  • 2     MARKET ANALYSIS
    • 2.1     INTRODUCTION
    • 2.2     FACTORS INFLUENCING MARKET
      • 2.2.1     DRIVERS AND OPPORTUNITIES
        • 2.2.1.1     Increasing trend of outsourcing
        • 2.2.1.2     Advanced bioprocessing capabilities of bioservice providers
        • 2.2.1.3     Emergence of next generation biologics
        • 2.2.1.4     Escalating approvals and uptake of biosimilars
        • 2.2.1.5     Increasing approvals and adoption of biologics
        • 2.2.1.6     Increasing R&D expenditures
        • 2.2.1.7     Increasing prevalence of chronic, communicable and autoimmune diseases
        • 2.2.1.8     Development of personalized and orphan indication therapies
      • 2.2.2     RESTRAINTS AND THREATS
        • 2.2.2.1     Increasing focus on in-house biologics manufacturing
        • 2.2.2.2     Huge capital investments for capacity and capability development
        • 2.2.2.3     Compliance with stringent regulatory guidelines
        • 2.2.2.4     Concerns about IP protection
        • 2.2.2.5     Competition and trend of outsourcing of low volume biologics
  • 3     BIOLOGICS OUTSOURCING GLOBAL MARKET, MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     BIOLOGICS OUTSOURCING GLOBAL MARKET BASED ON PHASE
      • 3.2.1     DISCOVERY AND PRE-CLINICAL DEVELOPMENT PROCESS
    • 3.3     BIOLOGICS OUTSOURCING GLOBAL MARKET, BASED ON PRODUCT TYPE
      • 3.3.1     ANTIBODY
        • 3.3.1.1     Monoclonal antibody
        • 3.3.1.2     Bispecific antibody
        • 3.3.1.3     Antibody drug conjugates
        • 3.3.1.4     Others (polyclonal antibody, antibody fragments)
      • 3.3.2     RECOMBINANT PROTEIN
      • 3.3.3     VACCINES
      • 3.3.4     GENE THERAPY
      • 3.3.5     CELL THERAPY
      • 3.3.6     OTHERS
    • 3.4     BIOLOGICS OUTSOURCING GLOBAL MARKET, BASED ON ENDUSERS
      • 3.4.1     THERAPEUTICS
      • 3.4.2     DIAGNOSTICS
      • 3.4.3     RESEARCH
    • 3.5     BIOANALYTICAL TESTING SERVICES
    • 3.6     MARKET SHARE ANALYSIS
    • 3.7     COMPANY DEVELOPMENTS
      • 3.7.1     AGREEMENT, COLLABORATIONS AND PARTNERSHIPS
      • 3.7.2     EXPANSION
      • 3.7.3     ACQUISITIONS
      • 3.7.4     FACILITY APPROVAL
      • 3.7.5     NEW PRODUCT, TECHNOLGY AND SERVICE LAUNCH
      • 3.7.6     OTHERS
    • 3.8     SERVICE COST ANALYSIS
      • 3.8.1     ANTIBODY PRODUCTION SERVICE COSTS
      • 3.8.2     CUSTOM MONOCLONAL ANTIBODY PRODUCTION SERVICE COSTS
      • 3.8.3     CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE COSTS
      • 3.8.4     PROTEIN PRODUCTION SERVICE COSTS
      • 3.8.5     ADDITIONAL ANTIBODY AND PROTEIN SERVICES
      • 3.8.6     GENE EDITTING SERVICES
      • 3.8.7     CAR-T/NK PLATFORM SERVICES
  • 4     BIOLOGICS OUTSOURCING GLOBAL MARKET - BIOMANUFACTURING
    • 4.1     INTRODUCTION
    • 4.2     MARKET DYNAMICS
    • 4.3     BIOLOGICS CMO GLOBAL MARKET BASED ON PRODUCT
      • 4.3.1     DRUG SUBSTANCE MANUFACTURING
      • 4.3.2     DRUG PRODUCT MANUFACTURING
    • 4.4     IN HOUSE VS CMO CAPACITY
      • 4.4.1     IN-HOUSE
      • 4.4.2     CMO
    • 4.5     GLOBAL BIOMANUFACTURING CAPACITY
    • 4.6     BIOLOGICS CONTRACT MANUFACTURING ORGANIZATIONS, BASED ON PHASE
      • 4.6.1     CLINICAL
      • 4.6.2     COMMERCIAL
    • 4.7     CONTRACT BIOMANUFACTURING, BASED ON PROCESS
      • 4.7.1     BIOMANUFACTURING BY MAMMALIAN CELL CULTURE
      • 4.7.2     MAMMALIAN CELL CULTURE BIOMANUFACTURING V/S MICROBIAL AND OTHER CELL CULTURES
      • 4.7.3     BIOMANUFACTURING BY MICROBIAL CELL CULTURE
      • 4.7.4     MICROBIAL CELL CULTURE CMO BIOMANUFACTURING CAPACITY
      • 4.7.5     BIOMANUFACTURING BY OTHER CELL CULTURE
    • 4.8     CONTRACT BIOMANUFACTURING GLOBAL MARKET, BASED ON END USERS
      • 4.8.1     CONTRACT BIOMANUFACTURING OF DIAGNOSTICS
      • 4.8.2     CONTRACT BIOMANUFACTURING OF RESEARCH REAGENTS
      • 4.8.3     CONTRACT BIOMANUFACTURING OF THERAPEUTICS
        • 4.8.3.1     BIOMANUFACTURING OF ANTIBODIES
        • 4.8.3.2     BIOMANUFACTURING OF RECOMBINANT PROTEINS
        • 4.8.3.3     BIOMANUFACTURING OF VACCINES
        • 4.8.3.4     GENE THERAPY, CELL THERAPY AND OTHER BIOLOGICS CONTRACT BIOMANUFACTURING
    • 4.9     BIOMANUFACTURING OUTSOURCING GLOBAL MARKET, BASED ON REGION
    • 4.10     VIRAL VECTOR & PLASMID DNA CONTRACT MANUFACTURING MARKET BASED ON VECTOR TYPE
      • 4.10.1     VIRAL VECTOR CONTRACT MANUFACTRUING
      • 4.10.2     PLASMID DNA CONTRACT MANUFACTRUING
    • 4.11     VIRAL VECTOR & PLASMID DNA CONTRACT MANUFACTURING MARKET, BASED ON MODALITY
      • 4.11.1     VACCINES
      • 4.11.2     CELL AND GENE THERAPIES
      • 4.11.3     OTHERS
    • 4.12     CONTRACT BIOMANUFACTURING CAPACITY PENETRATION
      • 4.12.1     CAPACITY COMPARISION
    • 4.13     STAINLESS STEEL VS SINGLE-USE FACILITIES
      • 4.13.1     STAINLESS STEEL FACILITY
      • 4.13.2     SINGLE-USE FACILITY
      • 4.13.3     COST OF GOODS COMPARSION BETWEEN STAINLESS STEEL AND SINGLE-USE FACILITIES
    • 4.14     COMPETATIVE LANDSCAPE
      • 4.14.1     CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY LEADING PLAYERS
      • 4.14.2     COMPANY DEVELOPMENTS
        • 4.14.2.1     EXPANSION
        • 4.14.2.2     COLLABORATION AND PARTNERSHIP
        • 4.14.2.3     AGREEMENT
        • 4.14.2.4     ACQUISITION
        • 4.14.2.5     FACILITY APPROVALS
        • 4.14.2.6     NEW PRODUCT, TECHNOLOGY AND SERVICE LAUNCH
        • 4.14.2.7     OTHER DEVELOPMENTS
  • 5     BIOLOGICS OUTSOURCING GLOBAL MARKET - CELL LINE DEVELOPMENT
    • 5.1     INTRODUCTION
      • 5.1.1     MARKET DYNAMICS
    • 5.2     CELL LINE DEVELOPMENT
      • 5.2.1     CELL LINE CONSTRUCTION
      • 5.2.2     HOST CELL LINE ENGINEERING EXPRESSION SYSTEM
      • 5.2.3     EXPRESSION VECTOR AND HOST CELL LINE ENGINEERING
      • 5.2.4     TRANSIENT GENE EXPRESSION
      • 5.2.5     STABLE CELL LINE DEVELOPMENT
      • 5.2.6     SCREENING
      • 5.2.7     UPSTREAM PROCESS DEVELOPMENT
    • 5.3     HOST CELL LINES
    • 5.4     CELL LINE DEVELOPMENT SERVICES MARKET, BASED ON EXPRESSION SYSTEM
      • 5.4.1     MAMMALIAN EXPRESSION SYSTEMS
      • 5.4.2     MICROBIAL EXPRESSION SYSTEMS
      • 5.4.3     OTHERS (INSECT AND PLANT CELL)
    • 5.5     CELL LINE DEVELOPMENT SERVICES, BASED ON CELL LINE TYPE
      • 5.5.1     CHO
      • 5.5.2     MURINE/MOUSE MYELOMA (NS0, SP2/0)
      • 5.5.3     BABY HAMSTER KIDNEY (BHK) CELLS
      • 5.5.4     HUMAN EMBRYONIC KIDNEY (HEK) CELLS
      • 5.5.5     HUMAN EMBRYONIC RETINAL CELLS (PER.C6)
      • 5.5.6     HYBRIDOMA
      • 5.5.7     OTHERS (E.COLI, YEAST, INSECT CELL, HT-1080, HELA CELL LINE, CAP, HKB-11, HUH-7)
    • 5.6     CELL LINE DEVELOPMENT SERVICES, BASED ON APPLICATIONS
      • 5.6.1     RESEARCH
      • 5.6.2     BIOPRODUCTION
      • 5.6.3     DIAGNOSTICS
    • 5.7     CELL BANKING SERVICES
    • 5.8     CELL LINE CHARACTERIZATION SERVICES
    • 5.9     MARKET SHARE ANALYSIS
    • 5.10     KEY DEVELOPMENTS
      • 5.10.1     AGREEMENT, COLLABORATION AND PARTNERSHIP
      • 5.10.2     NEW TECHNOLOGY, PRODUCT AND SERVICE LAUNCH
      • 5.10.3     OTHER DEVELOPMENTS
  • 6     COMPANY PROFILES
    • 6.1     ABBVIE INC.
      • 6.1.1     OVERVIEW
      • 6.1.2     FINANCIALS
      • 6.1.3     SERVICE PORTFOLIO
      • 6.1.4     KEY DEVELOPMENTS
      • 6.1.5     SWOT ANALYSIS
    • 6.2     AGC INC.
      • 6.2.1     OVERVIEW
      • 6.2.2     FINANCIALS
      • 6.2.3     SERVICE PORTFOLIO
      • 6.2.4     KEY DEVELOPMENTS
      • 6.2.5     SWOT ANALYSIS
    • 6.3     AVID BIOSERVICES, INC.
      • 6.3.1     OVERVIEW
      • 6.3.2     FINANCIALS
      • 6.3.3     SERVICE PORTFOLIO
      • 6.3.4     KEY DEVELOPMENTS
      • 6.3.5     SWOT ANALYSIS
    • 6.4     BOEHRINGER INGELHEIM INTERNATIONAL GMBH
      • 6.4.1     OVERVIEW
      • 6.4.2     FINANCIALS
      • 6.4.3     SERVICE PORTFOLIO
      • 6.4.4     KEY DEVELOPMENTS
      • 6.4.5     SWOT ANALYSIS
    • 6.5     CATALENT INC.
      • 6.5.1     OVERVIEW
      • 6.5.2     FINANCIALS
      • 6.5.3     SERVICE PORTFOLIO
      • 6.5.4     KEY DEVELOPMENTS
      • 6.5.5     SWOT ANALYSIS
    • 6.6     CHARLES RIVER LABORATORIES
      • 6.6.1     OVERVIEW
      • 6.6.2     FINANCIALS
      • 6.6.3     SERVICE PORTFOLIO
      • 6.6.4     KEY DEVELOPMENTS
      • 6.6.5     SWOT ANALYSIS
    • 6.7     CURIA
      • 6.7.1     OVERVIEW
      • 6.7.2     FINANCIALS
      • 6.7.3     SERVICE PORTFOLIO
      • 6.7.4     KEY DEVELOPMENTS
      • 6.7.5     SWOT ANALYSIS
    • 6.8     EMERGENT BIOSOLUTIONS INC.
      • 6.8.1     OVERVIEW
      • 6.8.2     FINANCIALS
      • 6.8.3     SERVICE PORTFOLIO
      • 6.8.4     KEY DEVELOPMENTS
      • 6.8.5     SWOT ANALYSIS
    • 6.9     EUROFINS SCIENTIFIC S.E.
      • 6.9.1     OVERVIEW
      • 6.9.2     FINANCIALS
      • 6.9.3     SERVICE PORTFOLIO
      • 6.9.4     KEY DEVELOPMENTS
      • 6.9.5     SWOT ANALYSIS
    • 6.10     FUJIFILM HOLDINGS CORPORATION (FUJIFILM DIOSYNTH BIOTECHNOL0GIES)
      • 6.10.1     OVERVIEW
      • 6.10.2     FINANCIALS
      • 6.10.3     SERVICE PORTFOLIO
      • 6.10.4     KEY DEVELOPMENTS
      • 6.10.5     SWOT ANALYSIS
    • 6.11     GENSCRIPT BIOTECH CORPORATION
      • 6.11.1     OVERVIEW
      • 6.11.2     FINANCIALS
      • 6.11.3     SERVICE PORTFOLIO
      • 6.11.4     KEY DEVELOPMENTS
      • 6.11.5     SWOT ANALYSIS
    • 6.12     JSR CORPORATION
      • 6.12.1     OVERVIEW
      • 6.12.2     FINANCIALS
      • 6.12.3     SERVICE PORTFOLIO
      • 6.12.4     KEY DEVELOPMENTS
      • 6.12.5     SWOT ANALYSIS
    • 6.13     LABORATORY CORP OF AMERICA HOLDINGS
      • 6.13.1     OVERVIEW
      • 6.13.2     FINANCIALS
      • 6.13.3     SERVICE PORTFOLIO
      • 6.13.4     KEY DEVELOPMENTS
      • 6.13.5     SWOT ANALYSIS
    • 6.14     LONZA GROUP LTD.
      • 6.14.1     OVERVIEW
      • 6.14.2     FINANCIALS
      • 6.14.3     SERVICE PORTFOLIO
      • 6.14.4     KEY DEVELOPMENTS
      • 6.14.5     SWOT ANALYSIS
    • 6.15     MERCK KGA
      • 6.15.1     OVERVIEW
      • 6.15.2     FINANCIALS
      • 6.15.3     PRODUCT PORTFOLIO
      • 6.15.4     KEY DEVELOPMENTS
      • 6.15.5     SWOT ANALYSIS
    • 6.16     NATIONAL RESILIENCE, INC.
      • 6.16.1     OVERVIEW
      • 6.16.2     FINANCIALS
      • 6.16.3     SERVICE PORTFOLIO
      • 6.16.4     KEY DEVELOPMENTS
      • 6.16.5     SWOT ANALYSIS
    • 6.17     RENTSCHLER BIOPHARMA SE
      • 6.17.1     OVERVIEW
      • 6.17.2     FINANCIALS
      • 6.17.3     SERVICE PORTFOLIO
      • 6.17.4     KEY DEVELOPMENTS
      • 6.17.5     SWOT ANALYSIS
    • 6.18     SAMSUNG BIOLOGICS CO. LTD.
      • 6.18.1     OVERVIEW
      • 6.18.2     FINANCIALS
      • 6.18.3     SERVICE PORTFOLIO
      • 6.18.4     KEY DEVELOPMENTS
      • 6.18.5     SWOT ANALYSIS
    • 6.19     THERMO FISHER SCIENTIFIC INC.
      • 6.19.1     OVERVIEW
      • 6.19.2     FINANCIALS
      • 6.19.3     SERVICE PORTFOLIO
      • 6.19.4     KEY DEVELOPMENTS
      • 6.19.5     SWOT ANALYSIS
    • 6.20     WUXI APPTEC CO., LTD.
      • 6.20.1     OVERVIEW
      • 6.20.2     FINANCIALS
      • 6.20.3     SERVICE PORTFOLIO
      • 6.20.4     KEY DEVELOPMENTS
      • 6.20.5     SWOT ANALYSIS
    • 6.21     WUXI BIOLOGICS (CAYMAN) INC.
      • 6.21.1     OVERVIEW
      • 6.21.2     FINANCIALS
      • 6.21.3     SERVICE PORTFOLIO
      • 6.21.4     KEY DEVELOPMENTS
      • 6.21.5     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     PATENT EXPIRY OF BIOLOGICS (2018 – 2030)
      • TABLE 2     BIOSIMILARS GLOBAL MARKET, BY REGION, (2021-2030) ($BN)
      • TABLE 3     HIGHLIGHTS OF THE REVISED GUIDELINES
      • TABLE 4     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY REGION (2021-2030) ($BN)
      • TABLE 5     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BASED ON PHASE (2021-2030) ($BN)
      • TABLE 6     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY PRODUCT (2021-2030) ($BN)
      • TABLE 7     LIST OF BIOLOGICS APPROVED (2015-2021)
      • TABLE 8     ANTIBODY OUTSOURCING GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2030) ($BN)
      • TABLE 9     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BASED ON END USERS (2021-2030) ($BN)
      • TABLE 10     AGREEMENT, COLLABORATIONS AND PARTNERSHIPS (2020-2022)
      • TABLE 11     EXPANSIONS (2020-2022)
      • TABLE 12     ACQUISITIONS (2020-2022)
      • TABLE 13     FACILITY APPROVAL (2020-2022)
      • TABLE 14     PRODUCT, TECHNOLOGY AND SERVICE LAUNCH (2020-2022)
      • TABLE 15     OTHER DEVELOPMENTS (2020 – 2022)
      • TABLE 16     SERVICE COMPARISON MATRIX OF THE COMPANY BASED ON BIOLOGICS TYPE
      • TABLE 17     BIOLOGICS CMO GLOBAL MARKET REVENUE, BASED ON PRODUCT ($ BN)(2021-2030)
      • TABLE 18     CAPACITY COMPARISON OF CONTRACT MANUFACTURING ORGANIZATIONS V’S IN-HOUSE CAPACITIES (L)(2021-2030)
      • TABLE 19     BIOLOGICS MANUFACTURED IN MAMMALIAN CELL CULTURE
      • TABLE 20     CONTRACT MANUFACTURING ORGANIZATIONS CAPACITY, BASED ON PROCESS (L)
      • TABLE 21     BIOLOGICS MANUFACTURED IN MICROBIAL CELL CULTURE
      • TABLE 22     BIOMANUFACTURING OUTSOURCING GLOBAL MARKET BASED ON END USERS, (2021-2030) ($BN)
      • TABLE 23     BIOMANUFACTURING OUTSOURCING GLOBAL MARKET BY REGION, (2021-2030) ($BN)
      • TABLE 24     VIRAL VECTOR & PLASMID DNA CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BASED ON VECTOR TYPE, (2021-2030) ($MN)
      • TABLE 25     VIRAL VECTOR & PLASMID DNA CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BASED ON MODALITY, (2021-2030) ($MN)
      • TABLE 26     CONTRACT BIOMANUFACTURING GLOBAL CAPACITY, BASED ON FACILITY (2021-2030) (L)
      • TABLE 27     STAINLESS STEEL CONTRACT BIOMANUFACTURING GLOBAL CAPACITY, BASED ON EXPRESSION SYSTEM (2021-2030) (L)
      • TABLE 28     SINGLE USE CONTRACT BIOMANUFACTURING GLOBAL CAPACITY, BASED ON EXPRESSION SYSTEM (2021-2030) (L)
      • TABLE 29     EXPANSION (2020 -2022)
      • TABLE 30     COLLABORATION AND PARTNERSHIP (2020-2022)
      • TABLE 31     AGREEMENT (2020 – 2022)
      • TABLE 32     ACQUISITION (2020 – 2022)
      • TABLE 33     FACILITY APPROVALS (2020 – 2022)
      • TABLE 34     NEW PEODUCT, TECHNOLOGY AND SERVICE LAUNCH
      • TABLE 35     OTHER DEVELOPMENTS (2020 – 2022)
      • TABLE 36     COMPANY COMPARISON MATRIX, BY MANUFACTURING CAPABILITY
      • TABLE 37     CELL LINE DEVELOPMENT SERVICES GLOBAL MARKET, BASED ON REGION, (2021-2030) ($MN)
      • TABLE 38     APPROVED BIOLOGICS AND CELL LINE TYPE (2015-2021)
      • TABLE 39     NUMBER OF APPROVED BIOLOGICS BY CELL LINE TYPE (2014-2020)
      • TABLE 40     CELL LINE DEVELOPMENT SERVICES GLOBAL MARKET, BASED ON EXPRESSION SYSTEM, (2021-2030) ($MN)
      • TABLE 41     CELL LINE DEVELOPMENT SERVICES GLOBAL MARKET, BASED ON CELL TYPE, (2021-2030) ($MN)
      • TABLE 42     CELL LINE TYPE OF SOME APPROVED BIOLOGICS MODALITIES AND CELL LINE TYPE
      • TABLE 43     CELL LINE DEVELOPMENT SERVICES GLOBAL MARKET, BY APPLICATION, (2021-2030) ($MN)
      • TABLE 44     CELL LINE DEVELOPMENT TECHNOLOGIES
      • TABLE 45     CELL LINE DEVELOPMENT SERVICES COST
      • TABLE 46     AGREEMENTS (2020 -2022)*
      • TABLE 47     NEW TECHNOLOGY, PRODUCT AND SERVICE LAUNCH (2020-2022)
      • TABLE 48     OTHERS (2020-2022)
      • TABLE 49     COMPARISON MATRIX OF CELL LINE DEVELOPMENT PLAYERS AND SERVICES OFFERED
      • TABLE 50     ABBVIE INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2) ($MN)
      • TABLE 51     ABBVIE INC.: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q2) ($MN)
      • TABLE 52     ABBVIE INC.: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q2) ($MN)
      • TABLE 53     AGC INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2) ($MN)
      • TABLE 54     AGC INC.: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q2) ($MN)
      • TABLE 55     AGC INC.: CHEMICALS REVENUE, BY SUB-SEGMENTS, (2020-2022) (Q2) ($MN)
      • TABLE 56     AGC INC.: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q2) ($MN)
      • TABLE 57     AVID BIOSERVICES, INC.: TOTAL REVENUE AND R&D EXPENSES, 2021-2023 (Q1) ($MN)
      • TABLE 58     BOEHRINGER INGELHEIM: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) ($MN)
      • TABLE 59     BOEHRINGER INGELHEIM: TOTAL REVENUE, BY SEGMENTS, (2019-2021) ($MN)
      • TABLE 60     BOEHRINGER INGELHEIM: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) ($MN)
      • TABLE 61     CATALENT INC: TOTAL REVENUE AND R&D EXPENSES (2020-2022) ($MN)
      • TABLE 62     CATALENT INC: TOTAL REVENUE, BY SEGMENT, (2020-2022) ($MN)
      • TABLE 63     CATALENT INC: TOTAL REVENUE, BY GEOGRPAHY, (2020-2022) ($MN)
      • TABLE 64     CHARLES RIVER LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2)($MN)
      • TABLE 65     CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q2) ($MN)
      • TABLE 66     CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q2) ($MN)
      • TABLE 67     EMERGENT BIOSOLUTIONS INC : TOTAL REVENUE AND R & D EXPENSES (2020-2022) (Q2) ($MN)
      • TABLE 68     EUROFINS SCIENTIFIC S.E. : TOTAL REVENUE AND R & D EXPENSES (2020-2022) (H1) ($MN)
      • TABLE 69     EUROFINS SCIENTIFIC S.E : TOTAL REVENUE, BY GEOGRAPHY, (2020-2021) (H1) ($MN)
      • TABLE 70     FUJIFILM HOLDINGS CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q1) ($MN)
      • TABLE 71     FUJIFILM HOLDINGS CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q1)($MN)
      • TABLE 72     FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q1) ($MN)
      • TABLE 73     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2)($MN)
      • TABLE 74     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q2) ($MN)
      • TABLE 75     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q2) ($MN)
      • TABLE 76     JSR CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2021-2023) (Q1) ($MN)
      • TABLE 77     JSR CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2021-2023) (Q1) ($MN)
      • TABLE 78     JSR CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2021-2023) (Q1) ($MN)
      • TABLE 79     LABORATORY CORPORATION: TOTAL REVENUE AND R&D EXPENSES (2020-2022) (Q2) ($MN)
      • TABLE 80     LABORATORY CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q2) ($MN)
      • TABLE 81     LABORATORY CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q2) ($MN)
      • TABLE 82     LONZA GROUP: TOTAL REVENUE & R&D EXPENSES (2020 -2022) (Q2) ($MN)
      • TABLE 83     LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2020 -2022) (Q2) ($MN)
      • TABLE 84     LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY (2020 -2022) (Q2) ($MN)
      • TABLE 85     MERCK KGA: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2) ($MN)
      • TABLE 86     MERCK KGA: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q2) ($MN)
      • TABLE 87     MERCK KGA: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q2) ($MN)
      • TABLE 88     SAMSUNG BIOLOGICS CO: TOTAL REVENUE (2020-2022) (Q2) ($MN)
      • TABLE 89     SAMSUNG BIOLOGICS: TOTAL REVENUE, BY GEOGRAPHY (2020-2022) (Q2)) ($MN)
      • TABLE 90     THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE AND R&D EXPENSES (2020-2022) (Q2) ($MN)
      • TABLE 91     THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE, BY SEGMENT, (2020-2022) (Q2) ($MN)
      • TABLE 92     THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE, BY GEOGRAPHY (2020-2022)(Q2) ($MN)
      • TABLE 93     WUXI APPTEC CO., LTD.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2) ($MN)
      • TABLE 94     WUXI APPTEC CO., LTD.: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q2) ($MN)
      • TABLE 95     WUXI APPTEC CO., LTD.: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q2) ($MN)
      • TABLE 96     WUXI BIOLOGICS: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2)($MN)
      • TABLE 97     WUXI BIOLOGICS: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q2) ($MN)
      • TABLE 98     WUXI BIOLOGICS: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q2) ($MN)

      LIST OF FIGURES

      • FIGURE 1     TOP SELLING DRUGS (2017 – 2021), SMALL MOLECULES V/S BIOLOGICS, (2017-2021)
      • FIGURE 2     TOP 30 BIOLOGICS PATENT EXPIRY, (2020-2032) AND RISE OF BIOSIMILARS
      • FIGURE 3     OUTLOOK OF BIOLOGICS GLOBAL MARKET (2020-2030) ($BN)
      • FIGURE 4     OUTLOOK OF CHINA BIOLOGICS MARKET (2020-2030) ($BN) AND CHINA BIOLOGICS OUTSOURCING MARKET (2020-2030) ($MN)
      • FIGURE 5     OUTLOOK OF INDIA BIOLOGICS MARKET (2020-2030) ($BN) AND INDIA BIOLOGICS OUTSOURCING MARKET (2020-2030) ($MN)
      • FIGURE 6     CHINA VS INDIA
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY REGION (2021-2030) ($BN)
      • FIGURE 9     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BASED ON PHASE (2022 V/S 2030) ($BN)
      • FIGURE 10     DISCOVERY BIOLOGICS OUTSOURCING MARKET REVENUE, BASED ON SERVICES 2022 ($ MN)
      • FIGURE 11     DISCOVERY BIOLOGICS OUTSOURCING MARKET, BASED ON SERVICE TYPE, 2022 ($MN)
      • FIGURE 12     BIOLOGICS OUTSOURCING GLOBAL MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2030) (%)
      • FIGURE 13     ANTIBODY OUTSOURCING GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE, (2022 V/S 2030) (%)
      • FIGURE 14     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BASED ON END-USERS (2022 V/S 2030) ($BN)
      • FIGURE 15     BIOLOGICS OUTSOURCING GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2022 (%)
      • FIGURE 16     KEY DEALS (2020-2022)
      • FIGURE 17     MARKET DYNAMICS OF CONTRACT BIOMANUFACTURING GLOBAL MARKET
      • FIGURE 18     GLOBAL MANUFACTURING CAPACITY, CGMP V’S NON-CGMP, INHOUSE V’S CMO, 2020-2030
      • FIGURE 19     CAPACITY UTILIZATION OF CONTRACT MANUFACTURING ORGANIZATIONS, BASED ON STAGE (MILLION LITERS) (2020-2030)
      • FIGURE 20     BIOLOGICS CMO GLOBAL MARKET REVENUE, BASED ON PHASE, (2020-2030) ($BN)
      • FIGURE 21     BIOLOGICS CMO GLOBAL MARKET REVENUE, BASED ON PROCESS, (2020-2030) ($BN)
      • FIGURE 22     GLOBAL CAPACITY COMPARISON OF MAMMALIAN, MICROBIAL AND OTHER CULTURE SYSTEMS (MN L) (2020-2030)
      • FIGURE 23     CMO CAPACITY COMPARISON OF MAMMALIAN, MICROBIAL AND OTHER CULTURE SYSTEMS (MN L) (2020-2030)
      • FIGURE 24     BIO-MANUFACTURING OUTSOURCING GLOBAL MARKET REVENUE, BASED ON END USERS, (2020-2030) ($BN)
      • FIGURE 25     ADC PIPELINE FOR CANCER (2020)
      • FIGURE 26     MONOCLONAL ANTIBODY PIPELINE FOR NON-CANCER INDICATIONS (2020)
      • FIGURE 27     MONOCLONAL ANTIBODY PIPELINE FOR CANCER (2020)
      • FIGURE 28     BIO-MANUFACTURING OUTSOURCING GLOBAL MARKET SHARE, BASED ON END USERS, (2022) ($BN)
      • FIGURE 29     OUTLOOK OF BIOLOGICS CMO GLOBAL MARKET SHARE, BY REGION 2022 (%) AND MANUFACTURING IN METRIC TONS, (2021-2030)
      • FIGURE 30     VIRAL VECTOR & PLASMID DNA CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BASED ON VECTOR TYPE (2022 VS 2030)
      • FIGURE 31     VIRAL VECTOR & PLASMID DNA CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BASED ON MODALITY (2022 VS 2030)
      • FIGURE 32     VECTORS USED IN GENE THERPY CLINCIAL TRIALS IN (2021)
      • FIGURE 33     CONTRACT BIOMANUFACTURING CAPACITY PENETRATION (2022)
      • FIGURE 34     CAPACITY COMPARISON OF TOP 20 CONTRACT MANUFACTURING ORGANIZATIONS (L)
      • FIGURE 35     CONTRACT BIOMANUFACTURING GLOBAL CAPACITY, BASED ON FACILITY (2022 VS 2030) (L)
      • FIGURE 36     STAINLESS STEEL CONTRACT BIOMANUFACTURING GLOBAL CAPACITY, BASED ON EXPRESSION SYSTEM (2022 VS 2030) (L)
      • FIGURE 37     SINGLE-USE CONTRACT BIOMANUFACTURING GLOBAL CAPACITY, BASED ON EXPRESSION SYSTEM (2022 VS 2030) (L)
      • FIGURE 38     CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY LEADING PLAYERS, 2022 (%)
      • FIGURE 39     KEY DEALS (2020 – 2022)
      • FIGURE 40     MARKET DYNAMICS OF CELL LINE DEVELOPMENT
      • FIGURE 41     CELL LINE DEVELOPMENT SERVICES GLOBAL MARKET SHARE, BY REGION, (2022 VS 2030) (%)
      • FIGURE 42     NUMBER OF APPROVED BIOLOGICS BY CELL LINE TYPE (2015-2021)
      • FIGURE 43     CELL LINE DEVELOPMENT SERVICES GLOBAL MARKET, BASED ON EXPRESSION SYSTEM, (2022 V/S 2030) ($MN)
      • FIGURE 44     EXPRESSION SYSTEMS OF SOME APPROVED BIOLOGICS (2015 – 2021)
      • FIGURE 45     CELL LINE DEVELOPMENT SERVICES GLOBAL MARKET, BASED ON CELL TYPE, (2022 V/S 2030) ($MN)
      • FIGURE 46     CELL LINE TYPE OF SOME APPROVED BIOLOGICS (NO’S) (2015-2021)
      • FIGURE 47     CELL LINE TYPE OF SOME APPROVED BIOLOGICS MODALITIES AND CELL LINE TYPE
      • FIGURE 48     CELL LINE DEVELOPMENT SERVICES GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2022 V/S 2030) ($MN)
      • FIGURE 49     CELL LINE DEVELOPMENT SERVCIES GLOBAL MARKET SHARE, BY LEADING PLAYERS (2022) (%)
      • FIGURE 50     KEY DEVELOPMENTS OF CELL LINE DEVELOPMENT SERVICES MARKET PLAYERS, (2020-2022)
      • FIGURE 51     OVERVIEW: ABBVIE INC.
      • FIGURE 52     SWOT: ABBVIE INC.
      • FIGURE 53     OVERVIEW: AGC INC.
      • FIGURE 54     SWOT: AGC INC.
      • FIGURE 55     SWOT: AVID BIOSERVICES, INC.
      • FIGURE 56     OVERVIEW: BOEHRINGER INGELHEIM
      • FIGURE 57     SWOT: BOEHRINGER INGELHEIM
      • FIGURE 58     OVERVIEW: CATALENT INC.
      • FIGURE 59     SWOT: CATALENT INC.
      • FIGURE 60     OVERVIEW: CHARLES RIVER LABORATORIES
      • FIGURE 61     SWOT: CHARLES RIVER LABORATORIES
      • FIGURE 62     SWOT: CURIA
      • FIGURE 63     SWOT: EMERGENT BIOSOLUTIONS
      • FIGURE 64     OVERVIEW: EUROFINS SCIENTIFIC
      • FIGURE 65     SWOT: EUROFINS SCIENTIFIC
      • FIGURE 66     OVERVIEW: FUJIFILM HOLDING CORPORATION
      • FIGURE 67     SWOT: FUJIFILM HOLDING CORPORATION
      • FIGURE 68     OVERVIEW: GENSCRIPT BIOTECH CORPORATION
      • FIGURE 69     SWOT: GENSCRIPT BIOSCIENCES CORPORATION
      • FIGURE 70     OVERVIEW: JSR CORPORATION
      • FIGURE 71     SWOT: JSR CORPORATION
      • FIGURE 72     OVERVIEW: LABORATORY CORP OF AMERICA HOLDINGS
      • FIGURE 73     SWOT: LABORATORY CORPORATION OF AMERICA HOLDINGS
      • FIGURE 74     OVERVIEW: LONZA GROUP
      • FIGURE 75     SWOT: LONZA GROUP
      • FIGURE 76     OVERVIEW: MERCK KGA
      • FIGURE 77     SWOT: MERCK KGAA
      • FIGURE 78     SWOT: NATIONAL RESILIENCE, INC.
      • FIGURE 79     SWOT: RENTSCHLER BIOPHARMA
      • FIGURE 80     SWOT: SAMSUNG BIOLOGICS
      • FIGURE 81     OVERVIEW: THERMO FISHER SCIENTIFIC
      • FIGURE 82     SWOT: THERMO FISHER SCIENTIFIC
      • FIGURE 83     OVERVIEW: WUXI APPTEC CO., LTD
      • FIGURE 84     SWOT: WUXI APPTEC CO., LTD
      • FIGURE 85     OVERVIEW: WUXI BIOLOGICS
      • FIGURE 86     SWOT: WUXI BIOLOGICS

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     3P Biopharmaceuticals
      • 2     53 biologics
      • 3     A & G Pharmaceutical Inc ( Precision Antibody)
      • 4     Abbvie Inc. (Abbvie Contract Manufacturing) (U.S.)
      • 5     Abzena PLC
      • 6     AGC Inc. (AGC Biologics)
      • 7     Ajinomoto Co. Inc. (Ajinomoto Biopharma services)
      • 8     Anthem Biosciences
      • 9     Applied StemCell, Inc. (ASC)
      • 10     Avid Bioservices Inc.
      • 11     Aragen Bioscience
      • 12     Biologics International Corp.
      • 13     Biovectra
      • 14     Biovian Oy
      • 15     Boehringer Ingelheim International GmbH
      • 16     BPS Bioscience, Inc
      • 17     Canton Biologics Co., Ltd
      • 18     Catalent Inc.
      • 19     Cellipont Bioservices.
      • 20     Celonic AG
      • 21     Center for Breakthrough Medicines (CBM)
      • 22     CJ Cheiljedang (Batavia Biosciences B.V.)
      • 23     Charles River Laboratories International Inc.
      • 24     Clean Biologics SAS (Biodextris)
      • 25     Creative Biolabs
      • 26     Curia (AMRI)
      • 27     Cytovance Biologics
      • 28     Danaher Corporation (Aldevron)
      • 29     EirGenix, Inc.
      • 30     Emergent Biosciences
      • 31     Eurofins Scientific S.E
      • 32     Evotec
      • 33     ExcellGene SA (Switzerland)
      • 34     Exothera S.A.
      • 35     Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)
      • 36     Forge Biologics
      • 37     Fusion Antibodies
      • 38     GC Biopharma (BioCentriq)
      • 39     Genezen
      • 40     Genscript Biotech Corporation
      • 41     Hepalink (Cytovance Biologics & SPL)
      • 42     Iberfar (Rodon Biologics )
      • 43     Icosagen Group
      • 44     Inotiv, Inc.
      • 45     Intertek Group plc
      • 46     IQVIA Holdings Inc (Q2 Solutions)
      • 47     JSR Corporation [JSR Life Sciences, LLC (KBI biopharma, Selexis SA, CrownBio)]
      • 48     Kemwell Biopharma
      • 49     Kun Tuo)
      • 50     Laboratory Corporation of America Holdings
      • 51     LFB Biomanufacturing
      • 52     Lonza Group Ltd.
      • 53     LSBio (Absolute antibody)
      • 54     Luina Bio Pty Ltd.
      • 55     Lykan Bioscience
      • 56     Matica Biotechnology, Inc. (Matica Bio)
      • 57     Merck KGaA
      • 58     Minaris Regenerative Medicine GmbH
      • 59     Mycenax
      • 60     National Resilience, Inc. (Therapure Biopharma Inc.)
      • 61     NecstGen
      • 62     Northway BiotechPharma
      • 63     OrganaBio
      • 64     Perkin Elmer (Horizon Discovery)
      • 65     Piramal Pharma Limited (PPL) (Yapan Bio Private Limited)
      • 66     Porton Advanced
      • 67     Premas Biotech
      • 68     ProBioGen AG
      • 69     ProMab Biotechnologies, Inc
      • 70     Proteogenix
      • 71     Recipharm
      • 72     Reliance Life Sciences
      • 73     Rentschler Biopharma SE
      • 74     RoslinCT
      • 75     Samsung Biologics Co. Ltd.
      • 76     Sartious AG
      • 77     SGS SA
      • 78     Sino Biological Inc.
      • 79     Syd labs
      • 80     Syngene International Ltd.
      • 81     The Antibody lab
      • 82     Thermo fisher Scientific Inc.
      • 83     Trenzyme GmbH
      • 84     ViroCell Biologics
      • 85     Viva Biotech Ltd
      • 86     VIVEbiotech
      • 87     VGXI, Inc.
      • 88     UGA Biopharma
      • 89     Wacker Chemie AG (Wacker Biotech GmbH)
      • 90     Wuxi Biologics
      • 91     Wuxi Apptech
      • 92     Yposkesi